MedTrace Logo

Drug-Drug Interaction Between PK101-001 and PK101-002

NCT03553316 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2019-05-24

No results posted yet for this study

Summary

To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.

Conditions

Interventions

DRUG

PK101-002

-(Single) PK101-002

COMBINATION_PRODUCT

PK101

-(Combination) PK101-001, PK101-002

Sponsors & Collaborators

  • PMG Pharm Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Seung-Hyun Kang · H Plus Yangji Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2019-03-22
Completion
2019-04-24

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553316 on ClinicalTrials.gov